Welcome to our dedicated page for Incannex Healthcare news (Ticker: IXHL), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Inc. reports company developments tied to its clinical-stage combination therapy pipeline, Nasdaq listing status and capital actions. Recurring updates describe IHL-42X, its oral fixed-dose combination program for obstructive sleep apnea, including clinical development strategy, sleep-medicine research partnerships and FDA Fast Track Designation.
News also covers PSX-001, the company’s oral synthetic botanical research compound formulation for generalized anxiety disorder, along with balance-sheet commentary, share repurchase activity, reverse stock split disclosures and Nasdaq minimum bid price compliance. The company’s communications generally center on clinical progress, regulatory context, financing capacity and public-company capital structure.
Incannex Healthcare (Nasdaq: IXHL) has commenced participant screening in its DReAMzz Phase 2 randomized crossover dose-confirmation study of IHL-42X for obstructive sleep apnea (OSA). Initial clinical sites are approved and actively screening, with additional sites to begin as regulatory permissions are obtained.
IHL-42X has FDA Fast Track designation, enabling more frequent FDA interactions and a potentially expedited review pathway. The DReAMzz study is designed to optimize dosing and assess both objective sleep metrics and patient-reported outcomes, building on earlier Phase 2 data that showed up to 83% reduction in Apnea-Hypopnea Index, significant improvements in fatigue and sleep-related impairment, and a favorable safety profile. OSA affects an estimated one billion people globally, and there are currently no FDA-approved oral pharmaceutical therapies for this condition.
Incannex (Nasdaq: IXHL) received a U.S. patent for IHL-42X, a proprietary oral combination therapy for obstructive sleep apnea (OSA). The patent, titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea,” covers composition and therapeutic methods with a baseline expiry of 9 July 2040.
According to Incannex, this grant strengthens its lead clinical asset, complements FDA Fast Track status and positive Phase II data, and supports the ongoing DReAMzz Phase 2 dose-optimisation study ahead of a planned Phase III program.
Incannex (Nasdaq: IXHL) received A$6,039,162.43 under the Australian R&D Tax Incentive Program and expects about A$5.1 million more in 2026, for over A$11.1 million total non-dilutive funding.
The funds strengthen its debt‑free balance sheet and support clinical programs such as IHL-42X and PSX-001, plus its active share repurchase program.
Incannex (Nasdaq: IXHL) announced that Alliance Global Partners has initiated equity research coverage with a BUY rating and a US$18.00 price target, in a report dated June 8, 2026 by analyst James Molloy.
The coverage evaluates Incannex’s clinical pipeline, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and is expected by the company to broaden investor awareness. AGP has received compensation from Incannex for investment banking services.
Incannex Healthcare (Nasdaq: IXHL) has officially commenced its DReAMzz clinical study of IHL-42X for obstructive sleep apnea (OSA). The crossover dose-optimization trial uses 14 clinical sites, with drug manufacturing, permits, and global distribution logistics in place.
The study aims to refine dosing and de-risk a planned Phase III program, building on positive Phase II RePOSA results and supported by FDA Fast Track designation for IHL-42X in OSA.
Incannex Healthcare (Nasdaq: IXHL) won the MedTech Breakthrough “Best New Technology Solution for Drug Development” award for its lead candidate IHL-42X, an oral combination therapy for obstructive sleep apnea (OSA).
According to Incannex, Phase 2 data showed statistically significant AHI reductions and improved oxygenation, sleep quality, and fatigue.
Incannex Healthcare (Nasdaq: IXHL) says its oral synthetic psilocybin program PSX-001 for Generalized Anxiety Disorder aligns with the White House Executive Order dated April 18, 2026. The company cites Phase 2 results showing a 12.8-point HAM-A reduction vs 3.6 placebo, 44% response and 27% remission in 73 patients.
Incannex reports no serious adverse events, an active U.S. IND, and over $70 million cash with no debt. The Executive Order could speed regulatory pathways but requires Phase 3 success for DEA rescheduling.
Incannex Healthcare (Nasdaq: IXHL) has reactivated its previously approved share repurchase program and executed repurchases over the past two trading days. The Board cited a belief that market valuation understates the company’s balance sheet, clinical progress, and future potential.
The company reported approximately $75 million in cash and no debt after recent financing, and stated that about $18.5 million remained available for repurchases as of December 31, 2025. The program is discretionary and may be modified, suspended, or discontinued.
Incannex Healthcare (Nasdaq: IXHL) has partnered with the AASM Foundation to sponsor a 2026 Focused Projects Grant for junior investigators in sleep apnea research and joined the Foundation’s Corporate Recognition Program.
Incannex continues advancing IHL-42X — an oral dronabinol/acetazolamide combination — after positive Phase 2 results, FDA Fast Track designation, and initiation of the DReAMzz Phase 2 dose-optimisation study with patient dosing expected within months toward a planned Phase 3 pathway.
Incannex (Nasdaq: IXHL) reported approximately $75 million in cash and no debt after a recent financing, while market capitalization is about $46 million, producing a negative enterprise value. Proceeds will fund the DReAMzz Phase 2 dose-optimization study for IHL-42X; PSX-001 development continues with an open IND.
The company expects to begin dosing in DReAMzz in the coming months and retains a board-approved share buyback program.